As of July 14, 2020, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease (COVID-19), has infected more than 13 million and killed nearly 600,000 individuals worldwide ([@bib1]). The predominant mode of morbidity and mortality in COVID-19 is respiratory failure related to acute lung injury and hypoxia ([@bib2], [@bib3]). Although the histopathological features in the airways and parenchyma of COVID-19 lungs are largely indistinguishable from those of other viral pneumonias, including influenza, there is mounting evidence to suggest that SARS-CoV-2 infection causes significant vascular damage, leading to pulmonary angiopathy ([@bib2], [@bib4], [@bib5]). Consistent with this notion, many patients present to medical attention with hypoxemia that is out of proportion to the severity of patient symptoms, leading in some cases to "silent hypoxia." Though the exact pathophysiological mechanisms for severe COVID-19 pneumonia are not fully known, provocatively, select autopsy series have shown diffuse thrombosis in the pulmonary microvasculature ([@bib4], [@bib5]). A deeper understanding of the underlying pathophysiology of COVID-19 and simple *in vivo* biomarkers are crucially needed to predict disease prognosis and to implement targeted precision therapy in these patients.

Computed tomography (CT) imaging of the chest has played a large role in the management of patients with COVID-19. However, to date, the literature has primarily focused on parenchymal abnormalities such as ground-glass opacities ([@bib6]). In this issue of the *Journal*, Patel and colleagues (pp. [690--699](10.1164/rccm.202004-1412OC)) ([@bib7]) evaluated pulmonary vasculature on CT imaging and its physiologic and hematologic correlates in mechanically ventilated patients with severe COVID-19 pneumonia. This retrospective study included 39 consecutive patients with acute COVID-19 respiratory failure who showed increased physiologic dead space as evidenced by reduced dynamic compliance (mean, 33.7 ml/cm H~2~O) and elevated ventilatory ratio (mean, 2.6), in agreement with previous results ([@bib8]) and suggestive of marked vascular involvement. Pulmonary vascular abnormalities were assessed by the presence of dilated peripheral vessels, identified as a vascular "tree-in-bud" pattern, as well as pulmonary perfusion abnormalities in a subset of 18 patients who were able to undergo dual-energy CT imaging. Vascular tree-in-bud was evident in 64% of the patients, who had at least two assessable lung lobes (i.e., without dense parenchymal opacification), whereas perfusion defects were present in all 18 patients who underwent dual-energy CT imaging. Additional laboratory investigations and thromboelastography indicated a state of hypercoaguability with reduced fibrinolysis specific to the pulmonary vasculature as a possible mechanism underlying the CT pulmonary vessel and perfusion abnormalities in these patients. Dilated pulmonary vessels ([@bib9], [@bib10]) and perfusion abnormalities ([@bib11]) have previously been noted in case reports and larger studies of COVID-19, and this work extends these findings with clinical correlates of pulmonary thrombosis.

The identification of pulmonary vascular tree-in-bud in COVID-19 is unique and interesting. CT tree-in-bud is most commonly reported in peripheral airways disease related to an infectious etiology ([@bib12]), whereas the vascular manifestation has only been reported in the context of pulmonary tumor thrombosis ([@bib12], [@bib13]). Here, Patel and colleagues ([@bib7]) showed an association between the presence of the vascular tree-in-bud pattern (yes vs. no) and duration of ventilation and hospitalization at the time of CT imaging, with a majority of patients who demonstrated vascular tree-in-bud on CT imaging experiencing 10 or more days of ventilation and hospitalization (both *P* = 0.01). These findings are intriguing, and it is tempting to speculate that the vascular tree-in-bud on CT imaging may be a prognostic biomarker for worse outcomes in COVID-19. Indeed, given the small sample size of this study, it may even be an exquisitely sensitive imaging biomarker. However, the posthospital outcomes in these patients were not stated in this study, and as such, it remains to be established whether vascular tree-in-bud is related to mortality in severe COVID-19.

A major limitation of this work is the lack of histopathological correlates of the *in vivo* CT findings. Autopsy of COVID-19 lungs strikingly shows diffuse microthromboses ([@bib4], [@bib5]), which is consistent with the idea that vascular tree-in-bud in COVID-19 represents an imaging phenotype of pulmonary thrombotic angiopathy, but direct comparison with histopathological specimens is required to confirm whether these are indeed thrombotic events. Future work relating postmortem histopathology to CT imaging acquired during hospitalization, even retrospectively, will allow for identification of *in vivo* factors and biomarkers that are predictive of mortality and can be used to target those patients who have the greatest risk for poor outcomes for appropriate treatment.

Many aspects of the pathophysiology and treatment of COVID-19 are still unclear ([@bib14]). In this work, Patel and colleagues ([@bib7]) have made an important contribution to the evolving understanding of pulmonary angiopathy in COVID-19. Whereas CT ground-glass opacities are common in COVID-19 but nonspecific, vascular tree-in-bud is a unique CT finding that may be indicative of poor prognosis in mechanically ventilated patients with severe COVID-19. [Figure 1](#fig1){ref-type="fig"} provides a schematic of the pulmonary angiopathy that likely drives CT vascular tree-in-bud in COVID-19 based on the current study ([@bib7]): pulmonary thrombosis caused by hypercoaguability and lack of fibrinolysis that enhances the peripheral pulmonary vessels on CT imaging. If the true cause of vascular tree-in-bud is determined, there is budding opportunity for vascular tree-in-bud as an *in vivo*, noninvasive biomarker of COVID-19 for prognosis, to enrich clinical trials for targeted therapy, and to evaluate treatment response and *n* = 1 precision treatment.

![Computed tomography (CT) vessel tree-in-bud schematic in coronavirus disease (COVID-19). Compared with normal pulmonary vessels (left), peripheral vessels in COVID-19 (middle) are resolved on CT imaging and demonstrate a tree-in-bud pattern. Hypercoagulability and lack of fibrinolysis in COVID-19 driving pulmonary thrombosis likely enhances the peripheral pulmonary vessels on CT imaging to cause the tree-in-bud pattern, although the direct pathologic cause is not yet determined.](rccm.202007-2833EDf1){#fig1}
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